HIGHLIGHTS
- who: October and colleagues from the Wayne State University, United States have published the paper: Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis, in the Journal: (JOURNAL) of 27/Dec/2018
SUMMARY
To 0.63; p=0.003) when compared to chemotherapy (Modi et_al, 2022). Surprisingly, T-DXd further showed significant antitumor activity for patients with HR+ (mOS, 23.9 months; mPFS, 10.1 months) or HR- (mOS, 18.2 months; mPFS, 8.5 months) HER2-low ABC (Modi et_al, 2022). Consequently, the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.